Pioneering the discovery of genetic modifiers to enable the development of transformative therapeutics
At Scenic we are generating a compendium of genomics data to identify genetic modifiers that suppress disease pathology. Many rare diseases are caused by an underlying genetic mutation. But across nearly all these patient populations there is a small subset of patients that have no or very mild disease traits. This is due to the presence of genetic modifiers — second (rare) mutations elsewhere in the genome that rebalance the disease state. Scenic’s Cell-Seq technology systematically unearths these genetic modifiers to inspire the development of transformative therapeutics. Scenic is active in the areas of rare metabolic diseases and inflammation.
Sebastian Nijman | Co-founder and CSO of Scenic Biotech BV
Sebastian received his scientific training at The Netherlands Cancer Institute and the Broad Institute of Harvard and M.I.T. He held a faculty position in Vienna at the CeMM before being appointed as an Associate Professor at the University of Oxford (Nuffield Department of Medicine). There, he held faculty positions as an Associate Member at the Ludwig Institute for Cancer Research and as Director of Functional Genomics at The Target Discovery Institute. Sebastian is a founder and former COO of Haplogen GmbH and a founder and former CEO of Scenic Biotech.
BIOTECH FAST FORWARD
POWERED BY:
© Copyright 2021 GenScript